ClinicalTrials.gg
CompletedNCT04818671ADAPTSC+Updated Jan 22, 2026Results posted

Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis

A Phase 3 interventional study of efgartigimod PH20 SC in Generalized Myasthenia Gravis, sponsored by argenx. Completed at 47 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-22.

Sponsored by argenx · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
184
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing efgartigimod alfa in Myasthenia Gravis — 11 open to participants now, 14 under way, 7 of them phase 3. efgartigimod alfa · Myasthenia Gravis.

Enrollment
Largest of 20
184 · median 55
Started
2021
with 3 others
Phase 3
10 of 20
3 open now
Registered
5th of 20
by date
Lead sponsor
12 of 20
argenx

Among the 20 studies testing efgartigimod alfa in Myasthenia Gravis, this one has the largest enrollment, is one of 4 that started in 2021, is one of 10 in phase 3, and was the 5th registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 144 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

11 of the 20 studies testing efgartigimod alfa in Myasthenia Gravis are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About efgartigimod alfa

efgartigimod alfa: first FDA approval 2021 (VYVGART), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing efgartigimod alfa in Myasthenia Gravis, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the long-term safety and tolerability of efgartigimod PH20 SC 1000 mg, and the clinical efficacy, PD, pharmacokinetics (PK), immunogenicity, impact on the quality of life (QoL) of the participants, treatment satisfaction, and administration method preference, and the feasibility of self- and caregiver-supported administration of the SC injection.

Treatment duration: 3-week treatment periods, repeated as needed with at least 28 days in between treatment periods

Health measurements: total levels of immunoglobulin G (IgG), Acetylcholine receptor binding autoantibodies (AChR-Ab) levels, Myasthenia Gravis Activities of Daly Living (MG-ADL).

03

Conditions studied

  • Generalized Myasthenia Gravis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must be capable of giving signed , which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  2. Previously participated in antecedent studies ARGX-113-2001 or ARGX-113-1705 and are eligible for roll over.
  3. use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies and:

    • Women of Child bearing potential () must have a negative urine pregnancy test at baseline before medicinal product (IMP) can be administered.

Exclusion criteria

Exclusion Criteria:

  1. The participant was discontinued early from studies ARGX-113-2001 or ARGX-113-1705, unless the reason for discontinuation from study ARGX-113-1705 was to roll over into study ARGX-113-2002.

    a. Participants who, in the investigator's judgment, are not benefiting from efgartigimod IV in study ARGX-113-1705 Part B are not eligible for roll over into ARGX-113-2002.

  2. Are pregnant or lactating, or intend to become pregnant during the study or within 90 days after the last dose of medicinal product (IMP)
  3. Has any of the following medical conditions:

    1. uncontrolled chronic bacterial, viral, or fungal infection at roll-over
    2. Any other known disease that, in the opinion of the investigator, would interfere with accurate assessment of clinical symptoms of myasthenia gravis or put the participant at undue risk
    3. History of unless deemed cured by adequate treatment with no evidence of reoccurrence for ≥3 years before the first administration of investigational medicinal product (IMP).

      Participants with the following cancers can be included at any time:

      • adequately treated basal cell or squamous cell skin cancer
      • carcinoma in situ of the cervix
      • carcinoma in situ of the breast
      • incidental histological findings of prostate cancer (TNM classification of malignant tumors stage T1a or T1b)
    4. Clinical evidence of other significant serious diseases, or the participant has had a recent major surgery, or who have any other condition that, in the opinion of the investigator, could confound the results of the study or put the participant at undue risk
  4. Received a within 28 days prior to study entry or plan to receive a live-attenuated vaccine during the study
  5. A known reaction to efgartigimod, rHuPH20, or any of its
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
184 participants (actual)

Study arms

  • Experimental
    efgartigimod PH20 SC

    Patients receiving efgartigimod PH20 subcutaneous (SC) treatment

    Biological: efgartigimod PH20 SC

Interventions

06

What researchers measure

Primary outcomes

  1. Number of AEs, SAEs and AESIs

    Adverse events, Serious Adverse event and Adverse events of special interest. Adverse events in the 'Infections and infestations' SOC were defined as AESIs because efgartigimod causes a transient reduction in total IgG levels.

    Time frame: Up to 3.5 years

Secondary outcomes

  1. MG-ADL Total Score Changes From Baseline

    The Myasthenia Gravis Activities of Daily Living (MG-ADL) is an 8-item patient-reported scale that assesses MG symptoms and their effects on daily activities. It evaluates a participant's capacity to perform different activities in their daily life. The total score ranges from 0 to 24 with higher scores indicating more impairment.

    Time frame: Up to week 4 of the first cycle

  2. Percent Change in Total IgG Levels From Baseline

    IgG: immunoglobulin G

    Time frame: Up to week 4 of the first cycle

  3. Percent Change in AChR-Ab From Baseline in AChR-Ab Seropositive Participants

    AchR-Ab: anti-acetylcholine receptor antibodies.

    Time frame: Up to week 4 of the first cycle

  4. Efgartigimod Serum Concentrations

    Time frame: Up to week 4 of the first cycle

  5. Incidence of ADAs Against Efgartigimod Over Time

    ADA: Anti-drug antibodies.

    Time frame: Up to 3.5 years

  6. Incidence of NAbs Against Efgartigimod Over Time

    NAbs: neutralizing antibodies

    Time frame: Up to 3.5 years

  7. Incidence of Antibodies Against rHuPH20 Over Time

    Time frame: Up to 3.5 years

  8. Incidence of NAbs Against rHuPH20 Over Time

    NAbs: neutralizing antibodies

    Time frame: Up to 3.5 years

  9. Changes in Total MG-QoL15r From Baseline

    Myasthenia Gravis Quality of Life 15 item scale revised (MG-QoL 15r) scores range from 0 to 30 with a higher score representing more severe symptoms.

    Time frame: Up to week 4 of the first cycle

  10. Changes in EQ-5D-5L VAS Score From Baseline

    EuroQoL 5 Dimensions 5-Level (EQ-5D-5L) visual analog scale (VAS) scores range from 0 to 100 with a higher score representing better health.

    Time frame: Up to week 4 of the first cycle

  11. Percent of Participants or Caregivers by Number of Training Visits Needed to be Competent to Start Self- or Caregiver-Supported Administration

    Time frame: Up to 3.5 years

  12. Percent of Self- or Caregiver-supported Study Drug Administration Among All Study Treatment Visits at Home

    Time frame: Up to 3.5 years

07

Results

Posted Jan 22, 2026

Participant flow

This study was conducted at 47 sites that enrolled participants in 12 countries. A total of 184 participants rolled over from ARGX-113-2001 and ARGX-113-1705, of whom 180 participants were exposed to efgartigimod PH20 SC treatment.

Participant flow — Overall Study
MilestoneEfgartigimod PH20 SC
Started180
Completed138
Not completed42
Withdrew: Withdrawal by subject16
Withdrew: Adverse event5
Withdrew: Lack of efficacy5
Withdrew: Death4
Withdrew: Physician decision4
Withdrew: Requires prohibited medication4
Withdrew: Lost to follow-up2
Withdrew: Approved drug available for indication1
Withdrew: Sponsor request1

Outcome measures

PrimaryNumber of AEs, SAEs and AESIs

Adverse events, Serious Adverse event and Adverse events of special interest. Adverse events in the 'Infections and infestations' SOC were defined as AESIs because efgartigimod causes a transient reduction in total IgG levels.

Time frame:
Up to 3.5 years
Reported as:
Number · events
Number of AEs, SAEs and AESIs
eventsEfgartigimod PH20 SC
Number of AEs3325
Number of SAEs107
Number of AESIs420
SecondaryMG-ADL Total Score Changes From Baseline

The Myasthenia Gravis Activities of Daily Living (MG-ADL) is an 8-item patient-reported scale that assesses MG symptoms and their effects on daily activities. It evaluates a participant's capacity to perform different activities in their daily life. The total score ranges from 0 to 24 with higher scores indicating more impairment.

Time frame:
Up to week 4 of the first cycle
Reported as:
Mean · score on a scale
MG-ADL Total Score Changes From Baseline
score on a scaleEfgartigimod PH20 SC
Cycle 1, Week 1-2.2 ± 0.20
Cycle 1, Week 2-3.4 ± 0.21
Cycle 1, Week 3-3.9 ± 0.22
Cycle 1, Week 4-4.0 ± 0.23
SecondaryPercent Change in Total IgG Levels From Baseline

IgG: immunoglobulin G

Time frame:
Up to week 4 of the first cycle
Reported as:
Mean · Percent change
Percent Change in Total IgG Levels From Baseline
Percent changeEfgartigimod PH20 SC
Percent Change in Total IgG Levels From Baseline-62.6 ± 0.93
SecondaryPercent Change in AChR-Ab From Baseline in AChR-Ab Seropositive Participants

AchR-Ab: anti-acetylcholine receptor antibodies.

Time frame:
Up to week 4 of the first cycle
Reported as:
Mean · Percent change
Percent Change in AChR-Ab From Baseline in AChR-Ab Seropositive Participants
Percent changeEfgartigimod PH20 SC
Percent Change in AChR-Ab From Baseline in AChR-Ab Seropositive Participants-57.6 ± 2.29
SecondaryEfgartigimod Serum Concentrations
Time frame:
Up to week 4 of the first cycle
Reported as:
Mean · ng/mL
Efgartigimod Serum Concentrations
ng/mLEfgartigimod PH20 SC
Efgartigimod Serum Concentrations21693 ± 8242
SecondaryIncidence of ADAs Against Efgartigimod Over Time

ADA: Anti-drug antibodies.

Time frame:
Up to 3.5 years
Reported as:
Count of participants · Participants
Incidence of ADAs Against Efgartigimod Over Time
ParticipantsEfgartigimod PH20 SC
Incidence of ADAs Against Efgartigimod Over Time35
SecondaryIncidence of NAbs Against Efgartigimod Over Time

NAbs: neutralizing antibodies

Time frame:
Up to 3.5 years
Reported as:
Count of participants · Participants
Incidence of NAbs Against Efgartigimod Over Time
ParticipantsEfgartigimod PH20 SC
Incidence of NAbs Against Efgartigimod Over Time11
SecondaryIncidence of Antibodies Against rHuPH20 Over Time
Time frame:
Up to 3.5 years
Reported as:
Count of participants · Participants
Incidence of Antibodies Against rHuPH20 Over Time
ParticipantsEfgartigimod PH20 SC
Incidence of Antibodies Against rHuPH20 Over Time49
SecondaryIncidence of NAbs Against rHuPH20 Over Time

NAbs: neutralizing antibodies

Time frame:
Up to 3.5 years
Reported as:
Count of participants · Participants
Incidence of NAbs Against rHuPH20 Over Time
ParticipantsEfgartigimod PH20 SC
Incidence of NAbs Against rHuPH20 Over Time1
SecondaryChanges in Total MG-QoL15r From Baseline

Myasthenia Gravis Quality of Life 15 item scale revised (MG-QoL 15r) scores range from 0 to 30 with a higher score representing more severe symptoms.

Time frame:
Up to week 4 of the first cycle
Reported as:
Mean · score on a scale
Changes in Total MG-QoL15r From Baseline
score on a scaleEfgartigimod PH20 SC
Cycle 1, Week 1-2.5 ± 0.29
Cycle 1, Week 2-3.7 ± 0.34
Cycle 1, Week 3-4.5 ± 0.38
Cycle 1, Week 4-4.7 ± 0.39
SecondaryChanges in EQ-5D-5L VAS Score From Baseline

EuroQoL 5 Dimensions 5-Level (EQ-5D-5L) visual analog scale (VAS) scores range from 0 to 100 with a higher score representing better health.

Time frame:
Up to week 4 of the first cycle
Reported as:
Mean · score on a scale
Changes in EQ-5D-5L VAS Score From Baseline
score on a scaleEfgartigimod PH20 SC
Changes in EQ-5D-5L VAS Score From Baseline13.9 ± 1.32
SecondaryPercent of Participants or Caregivers by Number of Training Visits Needed to be Competent to Start Self- or Caregiver-Supported Administration
Time frame:
Up to 3.5 years
Reported as:
Number · Percent of participants
Percent of Participants or Caregivers by Number of Training Visits Needed to be Competent to Start Self- or Caregiver-Supported Administration
Percent of participantsEfgartigimod PH20 SC
0 visits4.8
1 visit45.8
2 visits13.9
3 visits11.4
4 visits12.7
5 visits1.8
6 visits5.4
9 visits1.2
11 visits0.6
12 visits0.6
22 visits0.6
37 visits0.6
42 visits0.6
SecondaryPercent of Self- or Caregiver-supported Study Drug Administration Among All Study Treatment Visits at Home
Time frame:
Up to 3.5 years
Reported as:
Number · Percent
Percent of Self- or Caregiver-supported Study Drug Administration Among All Study Treatment Visits at Home
PercentEfgartigimod PH20 SC
Percent of Self- or Caregiver-supported Study Drug Administration Among All Study Treatment Visits at Home49.2

Adverse events

Collected over 3.5 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Efgartigimod PH20 SC5/180 (2.8%)55/180 (30.6%)167/180 (92.8%)
Most frequent serious events
Showing 10 of 65
Most frequent serious events
EventEfgartigimod PH20 SC
Myasthenia gravisNervous system disorders11/180
PneumoniaInfections and infestations7/180
COVID-19Infections and infestations4/180
Myasthenia gravis crisisNervous system disorders4/180
Respiratory failureRespiratory, thoracic and mediastinal disorders4/180
Angina unstableCardiac disorders2/180
Cardiac failure congestiveCardiac disorders2/180
CellulitisInfections and infestations2/180
SepsisInfections and infestations2/180
Rib fractureInjury, poisoning and procedural complications2/180
Most frequent other events
Showing 10 of 34
Most frequent other events
EventEfgartigimod PH20 SC
Injection site erythemaGeneral disorders55/180
COVID-19Infections and infestations52/180
HeadacheNervous system disorders48/180
NasopharyngitisInfections and infestations36/180
DiarrhoeaGastrointestinal disorders32/180
Upper respiratory tract infectionInfections and infestations32/180
Injection site bruisingGeneral disorders24/180
Injection site painGeneral disorders22/180
Back painMusculoskeletal and connective tissue disorders22/180
Injection site pruritusGeneral disorders21/180

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Efgartigimod PH20 SC
<=18 years0
Between 18 and 65 years139
>=65 years41
Age, Continuous
Age, Continuous(years)Efgartigimod PH20 SC
Mean50.8 ± 15.50
Sex: Female, Male
Sex: Female, Male(Participants)Efgartigimod PH20 SC
Female119
Male61
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Efgartigimod PH20 SC
Asian16
Black or African American2
White161
Multiple1
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Efgartigimod PH20 SC
Hispanic or Latino8
Not Hispanic or Latino172
08

Study locations

47 sites
  • Investigator site 6 - US0010032
    Carlsbad, California 92011, United States
  • Investigator Site 47 - US0010021
    Palo Alto, California 94304, United States
  • Investigator Site 45 - US0010108
    Boca Raton, Florida 33428, United States
  • Investigator site 4 - US0010110
    Port Charlotte, Florida 33952, United States
  • Investigator Site 39 - US0010006
    Tampa, Florida 41076, United States
  • Investigator Site 41 - US0010015
    Kansas City, Kansas 66160, United States
  • Investigator Site 46 - US0010111
    Amherst, New York 14226, United States
  • Investigator Site 38 - US0010003
    Chapel Hill, North Carolina 27514, United States
  • Investigator Site 44 - US0010077
    Durham, North Carolina 27710, United States
  • Investigator Site 42 - US0010019
    Cleveland, Ohio 44195, United States
  • Investigator site 7 - US0010008
    Cordova, Tennessee 38018, United States
  • Investigator Site 43 - US0010066
    Austin, Texas 78759, United States
  • Investigator Site 40 - US0010009
    San Antonio, Texas 78229, United States
  • Investigator site 5 - BE0320007
    Ghent, 9000, Belgium
  • Investigator site 24 - CZ4200005
    Brno, 625 00, Czechia
  • Investigator Site 32 - GEO9950004
    Tbilisi, K'alak'i T'bilisi 0160, Georgia
  • Investigator Site 33 - GEO9950016
    Tbilisi, K'alak'i T'bilisi 016, Georgia
  • Investigator site 2 - GEO9950002
    Tbilisi, 0112, Georgia
  • Investigator Site 1 - GEO9950001
    Tbilisi, 0114, Georgia
  • Investigator site 3 - GEO9950003
    Tbilisi, 0114, Georgia
  • Investigator Site 25 - DE490006
    Berlin, 10117, Germany
  • Investigator Site 26 - DE490009
    Münster, 48149, Germany
  • Investigator site 10 - HU0360013
    Budapest, 1082, Hungary
  • Investigator site 9 - HU0360012
    Budapest, 1204, Hungary
  • Investigator site 11 - IT0390003
    Milan, 20133, Italy
  • Investigator Site 34 - IT0390007
    Naples, 80138, Italy
  • Investigator Site 35 - IT0390008
    Roma, 00189, Italy
  • Investigator site 12 - JP0810002
    Chiba, Chiba-Shi 260-8677, Japan
  • Investigator Site 36 - JP0810055
    Sapporo, Hokkaido 063-0005, Japan
  • Investigator site 8 - JP0810004
    Hanamaki, Iwate 025-0082, Japan
  • Investigator Site 28- JP0810059
    Ōta-ku, Tokyo 143-8541, Japan
  • Investigator site 14 - JP0810007
    Osaka, 565-0871, Japan
  • Investigator Site 27 - JP0810008
    Sapporo, 060 8542, Japan
  • Investigator site 13 - JP0810005
    Sendai, 983-8520, Japan
  • Investigator site 15 - JP0810009
    Tokyo, 160-0023, Japan
  • Investigator site 16 - NL0310001
    Leiden, 2333, Netherlands
  • Investigator site 17 - PL0480001
    Gdansk, 80-952, Poland
  • Investigator site 19 - PL0480007
    Katowice, 40-123, Poland
  • Investigator site 22 - PL0480065
    Krakow, 31-426, Poland
  • Investigator site 18 - PL0480005
    Krakow, 31-505, Poland
  • Investigator site 20 - PL0480018
    Lublin, 20-093, Poland
  • Investigator site 21 - PL0480022
    Warsaw, 02-097, Poland
  • Investigator Site 29- RU0070002
    Novosibirsk, 630087, Russia
  • Investigator Site 30 - RU0070014
    Saint Petersburg, 194354, Russia
  • Investigator Site 37 - ES0340021
    Barcelona, 08035, Spain
  • Investigator Site 31 - ES0340038
    Barcelona, 08041, Spain
  • Investigator site 23 - ES0340039
    Valencia, 46026, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Dec 2024, 44 months.

Results were first posted in Jan 2026, 1 year after primary completion.

Of 43 industry-sponsored phase 3 interventional studies under Myasthenia Gravis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's 44 months is above that.

Counting every sponsor, half of 52 studies reached it within 30 months; a quarter within 20 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2021
First posted
Mar 26, 2021
StartActual
Apr 26, 2021
Primary completionActual
Dec 31, 2024
CompletionActual
Dec 31, 2024
Results first posted
Jan 22, 2026
Last update
Jan 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04818671
Lead sponsor
argenx
Responsible party
Sponsor
First posted
Mar 26, 2021
Start date
Apr 26, 2021
Primary completion
Dec 31, 2024
Completion
Dec 31, 2024
Results posted
Jan 22, 2026
Last update
Jan 22, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Efgartigimod alfa · Hyaluronidase (human recombinant)

Start the discussion